Sagimet BiosciencesSTU:0O2 -1.51%10 Operating Cash Flow per Share is €-1.05 as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,143 Biotechnology companies, Sagimet Biosciences ranks worse than 79% on this metric.
Sagimet Biosciences's operating cash flow per share for the
three
months ended in Mar. 2026 was €-0.23.
Sagimet Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.05.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -8.50% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -22.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Sagimet Biosciences's Operating Cash Flow per Share or its related term are showing as below:
STU:0O2'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -69.1 Med: -21.9 Max: -8.5
Current: -8.5
During the past 7 years, Sagimet Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was -8.50% per year. The lowest was -69.10% per year. And the median was -21.90% per year.
STU:0O2's 3-Year OCF Growth Rate is ranked worse than 79% of 1143
companies
in the Biotechnology industry
Industry Median: 16.8
vs STU:0O2: -8.50
Sagimet Biosciences Operating Cash Flow per Share Related Terms
Sagimet Biosciences Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences Operating Cash Flow per Share Chart
STU:0O2 vs EDIT, AUTL, FBRX: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.05
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of €-1.05 mean?
Sagimet Biosciences (STU:0O2) has a Operating Cash Flow per Share of €-1.05 as of Mar. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #903 out of 1143 companies in the Biotechnology industry, placing it in the top 79%.
Is Sagimet Biosciences' Operating Cash Flow per Share too high?
Sagimet Biosciences' current Operating Cash Flow per Share is €-1.05. Based on the distribution chart, Sagimet Biosciences ranks #903 out of 1143 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Operating Cash Flow per Share compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #903 out of 1143 companies for Operating Cash Flow per Share. This places Sagimet Biosciences in the lower half of its industry. The industry median Operating Cash Flow per Share is 16.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 16.80, based on 1,143 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 16.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current Operating Cash Flow per Share is €-1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Operating Cash Flow per Share of €-1.05. The current Operating Cash Flow per Share is €-1.05. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Operating Cash Flow per Share is €-1.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
